CN106666752A - 一种阿胶组合物及制备方法 - Google Patents
一种阿胶组合物及制备方法 Download PDFInfo
- Publication number
- CN106666752A CN106666752A CN201611206289.8A CN201611206289A CN106666752A CN 106666752 A CN106666752 A CN 106666752A CN 201611206289 A CN201611206289 A CN 201611206289A CN 106666752 A CN106666752 A CN 106666752A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- selenium
- corii asini
- colla corii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 108010010803 Gelatin Proteins 0.000 title abstract description 7
- 229920000159 gelatin Polymers 0.000 title abstract description 7
- 239000008273 gelatin Substances 0.000 title abstract description 7
- 235000019322 gelatine Nutrition 0.000 title abstract description 7
- 235000011852 gelatine desserts Nutrition 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title abstract description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 47
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 14
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000811 xylitol Substances 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 9
- 229960002675 xylitol Drugs 0.000 claims abstract description 9
- 235000010447 xylitol Nutrition 0.000 claims abstract description 9
- 108010052008 colla corii asini Proteins 0.000 claims description 34
- 239000002131 composite material Substances 0.000 claims description 10
- 230000003832 immune regulation Effects 0.000 claims description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 5
- -1 Fructose Oligosaccharide Chemical class 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 13
- 238000002512 chemotherapy Methods 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011669 selenium Substances 0.000 description 37
- 229940091258 selenium supplement Drugs 0.000 description 37
- 229910052711 selenium Inorganic materials 0.000 description 35
- 230000000694 effects Effects 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960003487 xylose Drugs 0.000 description 2
- 150000003742 xyloses Chemical class 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种免疫调节组合物及制备方法,阿胶5‑50份,加食用硒粉1‑8份。是3‑20份木糖醇或3‑20份低聚糖。3‑25份的L‑阿拉伯糖或加食用硒粉1‑8份,阿胶制备成粉状物或液体。添加3‑20份木糖醇与3‑20份低聚糖。或只添加3‑25份的L‑阿拉伯糖、食用硒粉与L‑阿拉伯糖一道添加。提出一种阿胶为主调节人体免疫能力的组合物,尤其是用于化疗前后的辅助健康食品,对三高人群甚至糖尿病患者调节免疫能力的组合物,更有利这类人群的对营养物质的吸收与滋养。
Description
技术领域
本发明涉及一种健康食品,特别涉及一种阿拉伯糖阿胶组合物及制备。
背景技术
中国传统滋补药材阿胶具有多种功效,如阿胶具有益智健脑作用:阿胶中含有的多种有效成分可以缓解学习紧张情绪,使大脑和全身得到充分休息,有利于提高体质,强身壮神,精力旺盛。阿胶中含有小子活性肽,能增强机体记忆力和提高识别能力,有较强抗疲劳作用。缓延衰老作用:阿胶含有明胶原、骨胶原、蛋白质以多种微量元素,多种氨基酸等。这些都是人体营养重要物质,有明显抗衰老、延年益寿作用。强筋健骨作用:阿胶补血液,血能养筋,液能润滑关节,充实骨髓、脊髓、脑髓,故能强筋健骨,流利关节,抗御风湿的伤害。具有补钙作用:阿胶中含有较丰富的钙质,通过甘氨酸的作用,促进钙的吸收和贮存,改善体内钙平衡,可预防和治疗骨质疏松。是中老年人保健中最为理想的补充剂。美容养颜作用:阿胶通过补血而滋润皮肤,利于皮肤保健。长期服用可使脸色红润,肌肤细嫩,有光泽。是滋养皮肤,美容养颜之佳品。调经安胎作用:阿胶可以用于因血虚、血瘀和血热引起的月 经不调,有利血调经作用。阿胶可补阴血,益冲任,故可养胎、安胎,调治妊娠病。对常见胎元不固,胎动不安,甚至流产有很好的治疗作用。扩张血管作用:实验证明阿胶对血液粘稠度增加有明显的抑制作用。中老年人服用阿胶可促进血液循环,改善微循环,抗心律不齐等作用,可使过高血压和过低血压恢复正常状态。
硒是人体中谷胱甘肽过氧化酶的组成部分之一,有保护细胞膜完整性的重要作用,同时还能增加细胞的免疫功能,提高中性粒细胞和巨噬细胞吞噬异物的作用,增加免疫球蛋白IgM、IgG的产生。含硒谷胱甘肽过氧化酶是一种自由基捕获剂,破坏体内的一切过氧化物。研究表明含硒量高的食物可明显抑制大鼠肝脏炎症的发展,如果食物中含硒最过低或缺乏,那么乙型肝炎表面抗原阳性率及肝癌的发生率就增高。
化疗的毒副反应主要是细胞的脂质过氧化,硒制剂可以抑制过氧化物,清除自由基和修复细胞损伤,调节机体代谢及其免疫功能。化疗前后使用较大剂量的硒制剂,白细胞总数及中性粒细胞数与不用硒剂比较明显提高,比粒细胞刺激因子一类药物经济或更有效。血液中硒的含量与胃肿瘤死亡率呈负相关。
微量元素硒对肝癌、乳腺癌、卵巢癌、胃癌、结肠癌、直肠癌、前列腺癌、肺癌等多种肿瘤具有显着的预防和治疗作用,而肿瘤的发生、发展均与硒的摄入不足有关,故重视及时补硒对肿瘤的预防和治疗有着重要帮助。目前,“硒与肿瘤关系的研究”已成为人们关注的话题,专家对硒预防和辅助治疗肿瘤的作用及其机理进行了广泛和深入的研究,并取得了多项重大进展,硒也因此被人们称为“抗癌之王”。
硒能“解除”致癌物的毒性:致癌物是肿瘤发生的最大诱因,硒能够促使某些致癌物代谢,降低其致癌性,从而达到防癌抗癌的目的。
硒能“抑制”肿瘤细胞增殖并促其凋亡:硒可抑制肿瘤细胞生长发育,并干扰其扩播的环节。大量研究已经证明,硒的特殊代谢产物通过不同途径进入癌组织,可有效地抑制肿瘤细胞的复制,促进其凋亡。
硒能“切断”肿瘤营养供给:肿瘤的成长依赖于机体对其的营养供给,硒可促进机体快速产生“抗肿瘤新生血管生成的抑制因子”,从而抑制肿瘤新生血管网的形成与发展,切断肿瘤细胞的营养供应渠道。由于肿瘤得不到营养来源,会逐渐“枯萎、消亡”;同时由于切断了肿瘤的代谢渠道,废物不能排出,肿瘤将逐渐变性坏死,其机制可形象地比喻为“断敌粮草”和“釜底抽薪”。富硒灵芝,富硒酵母,尤其是后者的硒含量更高。
发明内容
本发明的是,提出一种阿胶为主调节人体免疫能力的组合物,尤其是用于化疗前后的辅助健康食品,更可以是健康人群或亚健康人群的提高人体免疫能力的健康食品,更提出一种阿拉伯糖加阿胶或再加硒组合物及制备方法,对三高人群甚至糖尿病患者调节免疫能力的组合物,更有利这类人群的对营养物质的吸收与滋养。
本发明技术方案是,一种免疫调节组合物及制备方法,具有如下质量份,阿胶5-50份,食用硒粉1-8份。阿胶制备成粉状物添加。
一种免疫调节组合物及制备方法,具有如下质量份,阿胶5-50份,3-25份的L-阿拉伯糖或再加食用硒粉1-8份。阿胶制备成粉状物或液体,阿胶液可采用传统的黄酒或其它食用溶剂。
进一步的,3-20份木糖醇或/与3-20份低聚糖。
进一步的,添加大蒜,大蒜可以是大蒜粉或大蒜油或其它大蒜提取物5-30份。
进一步的,添加3-20份木糖醇加3-20份低聚木糖;木糖醇加低聚木糖加适量调味剂。
组合物优化肠道生态,L-阿拉伯糖、木糖醇和低聚糖、阿胶、食用硒粉在肠道中与微生物菌落和细胞体的交互影响,因此能够具有更好调节人体的健康的功效。
本发明可以制备成固体制剂,可以是片剂、胶囊、粉末剂、滴丸;也可以是制备成液体制剂,典型的是混悬剂,瓶子遮光、深棕色。
阿拉伯糖采用生物发酵提取的纯度达99.0%以上的L-阿拉伯糖;L-阿拉伯糖:木糖醇组分质量比为1-1.4:1-4;
低聚糖包括:果糖低聚糖、聚葡萄糖、半乳糖低聚糖、低聚木糖、低聚异麦芽糖、低聚乳糖、大豆低聚糖。
本发明所述组合物中阿胶的日用量高于5,以g为单位。
有益效果:阿胶还具有抗癌作用:实验观察发现阿胶对细胞免疫有双向调节作用。并对NK细胞的活性有较好的增强作用,而NK细胞在阻抑肿瘤的发生中起到一定的作用。此外,阿胶有促进健康人淋巴细胞转化作用,同时也能提高肿瘤患者的淋巴细胞转化率,用以辅助抗癌,可使肿瘤生长减慢,症状改善,生命延长。在使用放疗、化疗时,使用阿胶,可减少副作用,增强体质,增强药物耐受性。提高免疫力作用:阿胶对年老体弱,久病体虚,易患感冒等体质下降者有较好的治疗和预防作用,使免疫力增强,疾病减少。硒制剂能“提高”人体免疫及抗氧化能力:首先,硒可提高人体免疫力,对抗肿瘤细胞的复制和转移,这是由于硒几乎存在于人体的每一种免疫细胞中,缺硒可导致免疫力大幅度降低,补硒可调节人体最基本的三大免疫功能,即细胞免疫、体液免疫和非特异性免疫,从而全面提高人体防癌抗癌能力。其次,有害自由基增多是致癌的重要原因之一,硒可调节多种具有抗氧化功能的“含硒酶”的活性,清除有害自由基,保护细胞膜不受损害,预防肿瘤的发生。
阿胶与硒的组合具有互相增效作用,化疗前后使用较大剂量的硒制剂,白细胞总数及中性粒细胞数与不用硒剂比较明显提高,比粒细胞刺激因子一类药物经济或更有效。提高中性粒细胞和巨噬细胞吞噬异物的作用,增加免疫球蛋白IgM、IgG的产生,正好激活阿胶免疫球蛋白的作用,对人机体诱发干扰素及增强nk细胞的活性,巨噬细胞活化实现的。效果证明:通过阿胶硒粉对矽肺鼠的免疫功能影响实验研究,结果表明胸腺细胞增殖反应和脾细胞增殖反应有增加。
本发明基于肠道吸收,排除血糖升高的副作用,并充分利用阿胶、硒粉的免疫调节增强作用:硒是人体中谷胱甘肽过氧化酶的组成部分之一,有保护细胞膜完整性的重要作用,同时还能增加细胞的免疫功能,含硒谷胱甘肽过氧化酶是一种自由基捕获剂,破坏体内的一切过氧化物。含硒量高的食物可明显抑制大鼠肝脏炎症的发展,如果食物中含硒最过低或缺乏;因化疗的毒副反应主要是细胞的脂质过氧化,硒制剂可以抑制过氧化物,清除自由基和修复细胞损伤,调节机体代谢及其免疫功能。L-阿拉伯糖的反吸收糖份的作用,因此,可以控制人血糖升高,使得阿拉伯糖组合物在糖尿病人使用化疗辅助药物时能够充分采集吸收营养,无需忌口,长期服用能大大改善身体机能、强健身体。
本发明还具有其它综合的机理,优化肠道与生态,应该基于L-阿拉伯糖和低聚糖等在肠道中与微生物菌落和细胞体的交互影响,体细胞不但吸收养分,受激于有益因子,刺激有益成份产生,更深刻的影响在于营养和强壮肠道细胞,在吸收有益刺激物质(包括产生的酶、肽、和小分子蛋白质),因此能够调节人体的免疫;除了表面上明显改善了排便,是肠道因L-阿拉伯糖阻碍了肠对糖的吸收,低聚糖糖元又成为益生菌的营养原,更刺激了益生菌分泌有益产物。从生命的本源上来说,肠道为后天之本,健康的肠道是吸收运化食物及各种营养品的营养,健康的肠道又是功能与体积最大的免疫器官,本发明立足于肠道的营养、滋养和保健可以充分提高肠道的运化能力。
具体实施方式
下面结合具体实施例对本发明做进一步的详细说明。
本发明的组合物可以制成适于人使用的任何剂型。给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂、微乳、混悬剂;固体制剂可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、口腔崩解片等)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、粉剂等;本发明的剂型可使用惯常使用的任何方法。
阿胶5-50份,食用硒粉2-8份均可,采用酵母硒粉。或只添加3-25份的L-阿拉伯糖;或食用硒粉与L-阿拉伯糖一道添加。
进一步的,添加大蒜,大蒜可以是大蒜粉或大蒜油或其它大蒜物。
进一步的,添加大蒜;
进一步的,添加3-20份木糖醇加3-20份低聚木糖。
实施例1-19(质量单位份=g)
以上实施例均为一天的食用量,以上所述的具体实施方式,对本发明的目的、技术方案和有益效果进行了进一步详细说明,所应理解的是,以上所述仅为本发明的具体实施方式而已,并不用于限定本发明的保护范围,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种免疫调节组合物及制备方法,其特征是具有如下质量份,阿胶5-50份,食用硒粉1-8份,阿胶制备成粉状物或液体。
2.根据权利要求1所述的免疫调节组合物及制备方法,其特征是具有如下质量份,阿胶5-50份,3-25 份的 L- 阿拉伯糖或加食用硒粉1-8份,阿胶制备成粉状物或液体。
3.根据权利要求1或2所述的免疫调节组合物及制备方法,其特征是3-20 份木糖醇或3-20 份低聚糖。
4.根据权利要求3所述的免疫调节组合物及制备方法,其特征是添加3-20 份木糖醇与3-20 份低聚糖。
5.根据权利要求2或3所述的免疫调节组合物及制备方法,其特征是阿拉伯糖采用生物发酵提取的纯度达99.0%以上的L-阿拉伯糖。
6.根据权利要求3或4所述的免疫调节组合物及制备方法,其特征是低聚糖包括:果糖低聚糖、聚葡萄糖、半乳糖低聚糖、低聚木糖、低聚异麦芽糖、低聚乳糖、大豆低聚糖。
7.根据权利要求1或2所述的免疫调节组合物及制备方法,其特征是添加大蒜5-30份,大蒜为大蒜粉或大蒜油或其它大蒜提取物。
8.根据权利要求1或2所述的免疫调节组合物及制备方法,其特征是制备成固体制剂或液体制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611206289.8A CN106666752A (zh) | 2016-12-23 | 2016-12-23 | 一种阿胶组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611206289.8A CN106666752A (zh) | 2016-12-23 | 2016-12-23 | 一种阿胶组合物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106666752A true CN106666752A (zh) | 2017-05-17 |
Family
ID=58871398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611206289.8A Pending CN106666752A (zh) | 2016-12-23 | 2016-12-23 | 一种阿胶组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106666752A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107006661A (zh) * | 2017-06-13 | 2017-08-04 | 重庆大易科技投资有限公司 | 阿胶软糖及其制备方法 |
CN107981332A (zh) * | 2017-12-01 | 2018-05-04 | 深圳福山生物科技有限公司 | 一种阿胶组合物及其用途 |
CN115968808A (zh) * | 2022-12-30 | 2023-04-18 | 江苏欢欢宠物食品有限公司 | 一种冲压骨狗咬胶的加工工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102113611A (zh) * | 2011-02-25 | 2011-07-06 | 王以盘 | 一种美容防辐射护眼健瘦平衡阻糖的即食阿胶糕片及其制备方法 |
CN103766916A (zh) * | 2012-10-22 | 2014-05-07 | 孙莹 | 一种女性保健品及其制备方法 |
CN104431686A (zh) * | 2014-12-04 | 2015-03-25 | 中国科学院烟台海岸带研究所 | 一种富硒阿胶菊粉咀嚼片及其制备方法 |
-
2016
- 2016-12-23 CN CN201611206289.8A patent/CN106666752A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102113611A (zh) * | 2011-02-25 | 2011-07-06 | 王以盘 | 一种美容防辐射护眼健瘦平衡阻糖的即食阿胶糕片及其制备方法 |
CN103766916A (zh) * | 2012-10-22 | 2014-05-07 | 孙莹 | 一种女性保健品及其制备方法 |
CN104431686A (zh) * | 2014-12-04 | 2015-03-25 | 中国科学院烟台海岸带研究所 | 一种富硒阿胶菊粉咀嚼片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
迟玉杰: "《保健食品学》", 31 May 2016, 中国轻工业出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107006661A (zh) * | 2017-06-13 | 2017-08-04 | 重庆大易科技投资有限公司 | 阿胶软糖及其制备方法 |
CN107981332A (zh) * | 2017-12-01 | 2018-05-04 | 深圳福山生物科技有限公司 | 一种阿胶组合物及其用途 |
CN115968808A (zh) * | 2022-12-30 | 2023-04-18 | 江苏欢欢宠物食品有限公司 | 一种冲压骨狗咬胶的加工工艺 |
CN115968808B (zh) * | 2022-12-30 | 2023-11-03 | 江苏欢欢宠物食品有限公司 | 一种冲压骨狗咬胶的加工工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101822383A (zh) | 一种适用于肿瘤患者的功能性营养代餐食品及其制备方法 | |
CN104147132A (zh) | 能够降低血糖调节胰岛素分泌的软胶囊及制作方法 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN106616947A (zh) | 一种蛹虫草组合物 | |
CN106666752A (zh) | 一种阿胶组合物及制备方法 | |
CN103653009A (zh) | 一种美容养颜药膳乌鸡 | |
CN102551139A (zh) | 红枣黄芪减肥浓浆 | |
CN104856000A (zh) | 失眠非全营养配方食品 | |
CN104479964A (zh) | 一种黄秋葵、菌、藻保健酒及其制备方法 | |
CN103704568B (zh) | 临床膳食食品 | |
CN104872646A (zh) | 大肠癌非全营养配方食品 | |
CN104855960A (zh) | 创伤感染手术及其它应急状态非全营养配方食品 | |
CN102511876A (zh) | 山楂红枣浓浆 | |
CN104839704A (zh) | 壮阳非全营养配方食品 | |
CN104839699A (zh) | 心脏病非全营养配方食品 | |
CN104856008A (zh) | 萎缩性胃炎非全营养配方食品 | |
CN102511882A (zh) | 一种有助于改善生长发育的红枣浓浆 | |
CN106617031A (zh) | 一种獐宝免疫调节组合物及制备方法 | |
CN106035686A (zh) | 超级藜麦养生植物奶 | |
CN104872644A (zh) | 类风湿关节炎非全营养配方食品 | |
CN104855989A (zh) | 脾胃虚寒非全营养配方食品 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 | |
CN104839696A (zh) | 胃溃疡、十二指肠溃疡非全营养配方食品 | |
CN104921100A (zh) | 调理黄褐斑非全营养配方食品 | |
CN104432305A (zh) | 一种食疗功能饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |